Is the Size of Insulinoma Predictive for its Endocrine Behavior? An Endoscopic Ultrasound Study

Abstract

Objective Insulinoma is a rare tumor of the pancreas that can lead to spontaneous hypoglycemia due to excessive insulin secretion. Seventy-two-hour fast is the gold standard for finding the correct diagnosis. Endoscopic ultrasound (EUS) is an established examination method to identify the suspicious lesion. Previous studies correlate the measured size of insulinoma and their endocrine behavior. This study was designed to find a relation between these variables.

Methods We took the data of patients who had a histologically confirmed insulinoma after receiving an endoscopic ultrasound in our department. Size and echogenicity were correlated with the endpoint of the 72-hour fast and hormone levels.

Results A total of 45 patients were identified. Most insulinomas were small with a volume of<2 cm³ (median 1.15 cm³). There was no correlation between the duration of fasting, hormone levels, and the size of the insulinoma. In addition, in a subgroup analysis, no connection could be established between the size of the insulinoma and the amount of insulin released after oral glucose exposure. We found that homogeneous tumors were significantly smaller and had a lower Ki-67 index. Furthermore, there was a tendency towards a shorter duration for the 72-hour fast for the small tumors.

Discussion This data suggests that the measured size of insulinoma by EUS is not related to the time until termination of the 72-hour fast and measured hormone levels. The echogenicity seems more important, showing that homogenous tumors are an indicator of a higher differentiation, which can result in a shorter duration of the fasting period. The differences in the secretion behavior of the insulinomas could complicate the correlation of size and the 72-hour fast period.

Key words

insulinoma - insulin - endoscopic ultrasound - imaging - 72-hour fast - hypoglycemia - tumor size

Publication History

Received: 14 October 2021
Received: 03 April 2022

Accepted: 29 April 2022

Accepted Manuscript online:
02 May 2022

Article published online:
24 June 2022

• References

• 1 Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005; 19: 753-781 DOI: 10.1016/j.bpg.2005.06.002.
• 2 Shin JJ, Gorden P, Libutti SK. Insulinoma: Pathophysiology, localization and management. Future Oncol 2010; 6: 229-237 DOI: 10.2217/fon.09.165.
• 3 de Herder WW, Niederle B, Scoazec JY. et al. Well-differentiated pancreatic tumor/carcinoma: Insulinoma. Neuroendocrinology 2006; 84: 183-188 DOI: 10.1159/000098010.
• 4 Jensen RT, Cadiot G, Brandi ML. et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: Functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012; 95: 98-119 DOI: 10.1159/000335591.
• 5 Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol 2005; 19: 783-798 DOI: 10.1016/j.bpg.2005.05.008.
• 6 Cryer PE, Axelrod L, Grossman AB. et al. Evaluation and management of adult hypoglycemic disorders: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2009; 94: 709-728 DOI: 10.1210/jc.2008-1410.
• 7 Rinke A, Wiedenmann B, Auernhammer C. Practice guideline neuroendocrine tumors. In: AWMF online - Das Portal der wissenschaftlichen Medizin. 2018. 56. 583-681
• 8 Fendrich V, Bartsch DK, Langer P. et al. Diagnosis and surgical treatment of insulinoma-experiences in 40 cases. Dtsch Med Wochenschr 2004; 129: 941-946 DOI: 10.1055/s-2004-823060.
• 9 Giannis D, Moris D, Karachaliou GS. et al. Insulinomas: From diagnosis to treatment. A review of the literature. J BUON 2020; 25: 1302-1314
• 10 Andreassen M, Ilett E, Wiese D. et al. Surgical management, preoperative tumor localization, and histopathology of 80 patients operated on for insulinoma. J Clin Endocrinol Metab 2019; 104: 6129-6138 DOI: 10.1210/jc.2019-01204.
• 11 Martens P, Tits J. Approach to the patient with spontaneous hypoglycemia. Eur J Intern Med 2014; 25: 415-421 DOI: 10.1016/j.ejim.2014.02.011.
• 12 Nauck MA, Meier JJ. Spontanhypoglykämien. Diabetologe 2013; 9: 47-54
• 13 Donegan D, Jakubikova I, Vella A. Anthropometric features are not predictive of 72-hour fast duration in insulinomas. Endocr Pract 2017; 23: 923-928 DOI: 10.4158/EP171872.OR.
• 14 Wolf P, Winhofer Y, Smajis S. et al. Clinical presentation in insulinoma predicts histopathological tumour characteristics. Clin Endocrinol (Oxf) 2015; 83: 67-71 DOI: 10.1111/cen.12777.
• 15 Wright DB, London K, Field AP. Using bootstrap estimation and the plug-in principle for clinical Psychology Data. J Exp Psychopathol 2011; 2: 252-270
• 16 Kann PH. Endoscopic ultrasound imaging in neuroendocrine pancreatic tumors. A critical analysis. Med Klin (Munich) 2006; 101: 546-551 DOI: 10.1007/s00063-006-1064-2.
• 17 Sato Y, Hashimoto S, Mizuno K. et al. Management of gastric and duodenal neuroendocrine tumors. World J Gastroenterol 2016; 22: 6817-6828 DOI: 10.3748/wjg.v22.i30.6817.
• 18 Granberg D. Biochemical testing in patients with neuroendocrine tumors. Front Horm Res 2015; 44: 24-39 DOI: 10.1159/000381981.
• 19 Okabayashi T, Shima Y, Sumiyoshi T. et al. Diagnosis and management of insulinoma. World J Gastroenterol 2013; 19: 829-837 DOI: 10.3748/wjg.v19.i6.829.
• 20 Ielpo B, Caruso R, Ferri V. et al. Giant pancreatic insulinoma. The bigger the worse? Report of two cases and literature review. Int J Surg Case Rep 2013; 4: 265-268 DOI: 10.1016/j.ijscr.2012.11.019.
• 21 Mittendorf EA, Liu YC, McHenry CR. Giant insulinoma: Case report and review of the literature. J Clin Endocrinol Metab 2005; 90: 575-580 DOI: 10.1210/jc.2004-0825.
• 22 Kann PH. Is endoscopic ultrasonography more sensitive than magnetic resonance imaging in detecting and localizing pancreatic neuroendocrine tumors?. Rev Endocr Metab Disord 2018; 19: 133-137 DOI: 10.1007/s11154-018-9464-1.
• 23 Polenta V, Slater EP, Kann PH. et al. Preoperative imaging overestimates the tumor size in pancreatic neuroendocrine neoplasms associated with multiple endocrine neoplasia type 1. World J Surg 2018; 42: 1440-1447 DOI: 10.1007/s00268-017-4317-8.
• 24 Kann PH, Rothmund M, Zielke A. Endoscopic ultrasound imaging of insulinomas: Limitations and clinical relevance. Exp Clin Endocrinol Diabetes 2005; 113: 471-474 DOI: 10.1055/s-2005-865752.
• 25 Mathioudakis N, Pendleton C, Quinones-Hinojosa A. et al. ACTH-secreting pituitary adenomas: Size does not correlate with hormonal activity. Pituitary 2012; 15: 526-532 DOI: 10.1007/s11102-011-0362-8.
• 26 Buetow PC, Parrino TV, Buck JL. et al. Islet cell tumors of the pancreas: Pathologic-imaging correlation among size, necrosis and cysts, calcification, malignant behavior, and functional status. AJR Am J Roentgenol 1995; 165: 1175-1179 DOI: 10.2214/ajr.165.5.7572498.
• 27 Saddig C, Goretzki PE, Starke AA. Differentiation of insulin secretion patterns in insulinoma. World J Surg 2008; 32: 918-929 DOI: 10.1007/s00268-007-9450-3.
• 28 Henquin JC, Nenquin M, Guiot Y. et al. Human insulinomas show distinct patterns of insulin secretion in vitro. Diabetes 2015; 64: 3543-3553 DOI: 10.2337/db15-0527.
• 29 Boden G, Murer E, Mozzoli M. Glucose transporter proteins in human insulinoma. Ann Intern Med 1994; 121: 109-112 DOI: 10.7326/0003-4819-121-2-199407150-00005.
• 30 Berger C, Zdzieblo D. Glucose transporters in pancreatic islets. Pflugers Arch 2020; 472: 1249-1272 DOI: 10.1007/s00424-020-02383-4.
• 31 Kar P, Price P, Sawers S. et al. Insulinomas may present with normoglycemia after prolonged fasting but glucose-stimulated hypoglycemia. J Clin Endocrinol Metab 2006; 91: 4733-4736 DOI: 10.1210/jc.2006-1430.
• 32 Wiesli P, Schmid C, Perren A. et al. Hypoglycemia in response to glucose and glucagon in insulinoma patients with a negative prolonged fast: Functional and morphological properties. J Endocrinol Invest 2004; 27: 832-838 DOI: 10.1007/BF03346277.
• 33 Liao J, Ding F, Luo W. et al. Using the secretion ratios of insulin and C-peptide during the 2-h oral glucose tolerance test to diagnose insulinoma. Dig Dis Sci 2021; 66: 1533-1539 DOI: 10.1007/s10620-020-06379-z.
• 34 Kittah NE, Vella A. Management of endocrine disease: Pathogenesis and management of hypoglycemia. Eur J Endocrinol 2017; 177: R37-R47 DOI: 10.1530/EJE-16-1062.
• 35 Boyle PJ, Shah SD, Cryer PE. Insulin, glucagon, and catecholamines in prevention of hypoglycemia during fasting. Am J Physiol 1989; 256: E651-E661 DOI: 10.1152/ajpendo.1989.256.5.E651.
• 36 Nessa A, Rahman SA, Hussain K. Hyperinsulinemic hypoglycemia - The molecular mechanisms. Front Endocrinol (Lausanne) 2016; 7: 29 DOI: 10.3389/fendo.2016.00029.
• 37 Davis MR, Shamoon H. Deficient counterregulatory hormone responses during hypoglycemia in a patient with insulinoma. J Clin Endocrinol Metab 1991; 72: 788-792 DOI: 10.1210/jcem-72-4-788.
• 38 Ishigaki H, Yoshida A, Araki O. et al. Prolonged plasma glucose elevation on oral glucose tolerance test in young healthy Japanese individuals. Endocrinol Diabetes Metab 2020; 3: e00098 DOI: 10.1002/edm2.98.
• 39 Kann PH, Ivan D, Pfützner A. et al. Preoperative diagnosis of insulinoma: Low body mass index, young age, and female gender are associated with negative imaging by endoscopic ultrasound. Eur J Endocrinol 2007; 157: 209-213 DOI: 10.1530/EJE-07-0117.
• 40 Service FJ. Hypoglycemic disorders. N Engl J Med 1995; 332: 1144-1152 DOI: 10.1056/NEJM199504273321707.